|Bid||39.04 x 1300|
|Ask||39.66 x 1300|
|Day's Range||39.29 - 40.18|
|52 Week Range||29.85 - 59.46|
|Beta (5Y Monthly)||1.24|
|PE Ratio (TTM)||23.14|
|Earnings Date||Nov 06, 2023 - Nov 10, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.80|
Subscribe to Yahoo Finance Plus to view Fair Value for HALO
On September 19, 2023, Michael Labarre, the Senior Vice President and Chief Technical Officer of Halozyme Therapeutics Inc (NASDAQ:HALO), sold 10,000 shares of the company.
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.